Phase 2Active, not recruitingGeroscience intervention
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
- Sponsor
- Washington University School of Medicine (Academic or other)
- Enrollment
- 40 planned
- Conditions
- Schizophrenia; Treatment Resistant Depression; Aging, Premature
- Interventions
- Dasatinib; quercetin
- Ages
- adults, older adults
- Registry
- NCT05838560
Full record on ClinicalTrials.gov
From the registry
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
Primary outcomes
- Number of participants who successfully completed and safely tolerated the intervention
History
Primary completion expected
Last registry update
Started
Registered